KCT0007319
Not yet recruiting
未知
Development of treatment model and verification of a new integrated clinical subtype based on multi-dementional analysis on the common and differential mechanisms of cognitive dysfunction and depression in cognitive dysfunction with depression.
Hallym University Medical Center- Chuncheon0 sites500 target enrollmentTBD
ConditionsMental and behavioural disorders
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Mental and behavioural disorders
- Sponsor
- Hallym University Medical Center- Chuncheon
- Enrollment
- 500
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients over 55 years of age.
- •2\) A person who meets the diagnosis based on the following medical diagnosis.
- •\- Diagnosis of Alzheimer's dementia and mild cognitive impairment: A patient diagnosed based on the diagnostic criteria of DSM\-V and diagnostic impressions of CERAD\-K (Korean Version of the Concortium to Establish a Registry of Alzheimer's Disease) evaluation.
- •\- Depression Diagnosis: Patients diagnosed with major depressive disorder, minor depressive disorder, and subsymptomatic depressive disorder using MINI\-K.
- •3\) In the normal group, except for 2\).
- •4\) A person who can voluntarily decide to participate in this clinical trial, give written consent, and perform clinical procedures including filling out questionnaires. However, if the patient is unable to make a voluntary decision due to cognitive decline, his/her legal representative may decide to participate.
Exclusion Criteria
- •1\) Persons with serious medical illnesses (heart failure, angina pectoris, myocardial infarction, arteriosclerosis, diabetes, inflammatory disease, malignancy, etc.) or psychiatric disease other than AD and MCI diagnosis.
- •2\) Those diagnosed with bipolar or psychotic major depressive disorder.
- •3\) Those with a history of seizures, brain surgery, organic brain disease or organic emotional disorder, and abnormal findings other than brain atrophy on brain MRI.
- •4\) Those who are judged to have problems attaching EEG patches and near\-infrared electrodes due to scalp deformities, inflammatory reactions, or other dermatological problems.
- •5\) Those with a history of habitual drinking or drug abuse.
- •6\) Patients with uncontrolled diabetes or hypertension.
- •7\) Those who are judged to be inappropriate for this clinical trial by the investigator.
- •8\) Patients with severe dementia (GDS score of 7 or higher or CDR score of 4 or higher).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
The effect of combined treatment to reduce body dysmorphic disorder in womeBody dysmorphic disorder.Body dysmorphic disorderF45.22IRCT20220730055583N1Vice President of Research and Technology of Ferdowsi University of Mashhad Ferdowsi3
Completed
Not Applicable
Development of a comprehensive treatment based on psychosocial approach for support for the individuals with early psychosisPsychotic disorders A nurse working in a Psychiatric hospitalJPRN-UMIN000031268Tohoku University20
Active, not recruiting
Phase 1
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative early breast cancer populatioEarly-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth Factor Receptor 2 (HER2)-negative, breast cancer (BC)Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-505661-89-00Medica Scientia Innovation Research S.L.1,260
Active, not recruiting
Phase 2
Study to evaluate treatment efficacy by monitoring minimal residual disease in an early breast cancer populatioEarly breast cancerCancerISRCTN50261938Medica Scientia Innovation Research, S.L. (MEDSIR)1,260
Recruiting
Phase 2
Development of treatments for movement disorders by brain stimulation.central nervous system dysordersJPRN-jRCTs072220028Etoh Seiji30